ÔçëÝöùíá åðéêïéíùíßáò ôùí õðçñåóéþí ðñüíïéáò ãéá ôï åðßäïìá AIDS

Ößëôñï
ÍÏÌÏÓ ÄÇÌÏÓ ÔÇËÅÖÙÍÏ
ÁÉÔÙË/ÍÉÁÓÁÃÑÉÍÉÏÕ2641363400
ÁÉÔÙË/ÍÉÁÓÁÌÖÉËÏ×ÉÁÓ2642022266
ÁÉÔÙË/ÍÉÁÓÉ.Ð ÌÅÓÏËÏÃÃÉÏÕ2631363432
ÁÉÔÙË/ÍÉÁÓÍÁÕÐÁÊÔÉÁÓ2634361218
ÁÑÃÏËÉÄÁÓÍÁÕÐËÉÅÙÍ2752029243
ÁÑÊÁÄÉÁÓÔÑÉÐÏËÇÓ2713600418
ÁÑÔÇÓÁÑÔÁÉÙÍ2681362106
ÁÔÔÉÊÇÓÁÃÉÁÓ ÐÁÑÁÓÊÅÕÇÓ2132100603
ÁÔÔÉÊÇÓÁÈÇÍÁÉÙÍ2105210649
ÁÔÔÉÊÇÓÁÉÃÁËÅÙ2132044824
ÁÔÔÉÊÇÓÁ×ÁÑÍÙÍ2102415380
ÁÔÔÉÊÇÓÅËÅÕÓÉÍÁÓ2131601403
ÁÔÔÉÊÇÓÊÁËËÉÈÅÁÓ2109532717
ÁÔÔÉÊÇÓÍÉÊÁÉÁÓ - ÁÃ.ÉÙÁÍÍÇ ÑÅÍÔÇ2132004813
ÁÔÔÉÊÇÓÐÁËËÇÍÇÓ2106604718
ÁÔÔÉÊÇÓÐÅÉÑÁÉÙÓ2131601870
ÁÔÔÉÊÇÓÓÁËÁÌÉÍÁÓ2132027580
Á×ÁÉÁÓÐÁÔÑÅÙÍ2610390970
ÂÏÉÙÔÉÁÓËÅÂÁÄÅÙÍ2261024984
ÃÑÅÂÅÍÙÍÃÑÅÂÅÍÙÍ2462353038
ÄÑÁÌÁÓÄÑÁÌÁÓ2521351123
ÄÙÄÅÊÁÍÇÓÏÕÑÏÄÏÕ2241044741
ÅÂÑÏÕÁËÅÎÁÍÄÑÏÕÐÏËÇÓ2551081045
ÅÕÂÏÉÁÓ×ÁËÊÉÄÅÙÍ2221061232
ÅÕÑÕÔÁÍÉÁÓÊÁÑÐÅÍÇÓÉÏÕ2237080238
ÆÁÊÕÍÈÏÕÆÁÊÕÍÈÏÕ2695042544
ÇËÅÉÁÓÐÕÑÃÏÕ2621360430
ÇÌÁÈÉÁÓÂÅÑÏÉÁÓ2331351918
ÇÑÁÊËÅÉÏÕÇÑÁÊËÅÉÏÕ2813409530
ÈÅÓÐÑÙÔÉÁÓÇÃÏÕÌÅÍÉÔÓÁÓ2665099983
ÈÅÓÓÁËÏÍÉÊÇÓÈÅÓÓÁËÏÍÉÊÇÓ2313330322
ÉÙÁÍÍÉÍÙÍÉÙÁÍÍÉÔÙÍ2651001041
ÊÁÂÁËÁÓÊÁÂÁËÁÓ2513503348
ÊÁÑÄÉÔÓÁÓÊÁÑÄÉÔÓÁÓ2441354719
ÊÁÓÔÏÑÉÁÓÊÁÓÔÏÑÉÁÓ2467350206
ÊÅÑÊÕÑÁÓÊÅÑÊÕÑÁÓ2661035395
ÊÅÖÁËËÇÍÉÁÓÊÅÖÁËËÏÍÉÁÓ-ÉÈÁÊÇÓ2671022506
ÊÉËÊÉÓÊÉËÊÉÓ2341352277
ÊÏÆÁÍÇÓÊÏÆÁÍÇÓ2461029497
ÊÏÑÉÍÈÉÁÓÊÏÑÉÍÈÉÙÍ2741085890
ÊÕÊËÁÄÙÍÓÕÑÏÕ - ÅÑÌÏÕÐÏËÇÓ2281079648
ËÁÊÙÍÉÁÓÓÐÁÑÔÇÓ2731022226
ËÁÑÉÓÁÓËÁÑÉÓÓÁÉÙÍ2413549225
ËÁÓÉÈÉÏÕÁÃÉÏÕ ÍÉÊÏËÁÏÕ2841340391
ËÅÓÂÏÕËÅÓÂÏÕ2251048214
ËÅÓÂÏÕËÇÌÍÏÕ2254024011
ËÅÕÊÁÄÏÓËÅÕÊÁÄÁÓ2645360615
ÌÁÃÍÇÓÉÁÓÂÏËÏÕ2421353162
ÌÅÓÓÇÍÉÁÓÊÁËÁÌÁÔÁÓ2721361858
ÎÁÍÈÇÓÎÁÍÈÇÓ2541350124
ÐÅËËÁÓÅÄÅÓÓÁÓ2381351275
ÐÉÅÑÉÁÓÊÁÔÅÑÉÍÇÓ2351351280
ÐÑÅÂÅÆÇÓÐÑÅÂÅÆÁÓ2682089214
ÑÅÈÕÌÍÏÕÑÅÈÕÌÍÇÓ2831341243
ÑÏÄÏÐÇÓÊÏÌÏÔÇÍÇÓ2531022535
ÓÁÌÏÕÓÁÌÏÕ2273080411
ÓÅÑÑÙÍÓÅÑÑÙÍ2321055656
ÔÑÉÊÁËÙÍÔÑÉÊÊÁÉÙÍ2431063201
ÖÈÉÙÔÉÄÁÓËÁÌÉÅÙÍ2231350125
ÖËÙÑÉÍÁÓÖËÙÑÉÍÁÓ2385044479
ÖÙÊÉÄÁÓÄÅËÖÙÍ2265350531
×ÁËÊÉÄÉÊÇÓÐÏËÕÃÕÑÏÕ2371351449
×ÁÍÉÙÍ×ÁÍÉÙÍ2821341691
×ÉÏÕ×ÉÏÕ2271350050
+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò